Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + SOX for unresectable gastric cancer
NCT03007446Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03007446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007446.